u/copay_card_cc

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

Correction to my own post above — I said 12.5mg and I have been on 5mg since the spring. Same argument, wrong number.

Dose reduction and interval extension are different interventions. Halving the dose keeps the rhythm and lowers the level; stretching keeps the level and lowers the frequency, with a lower trough.

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

That is a non-fasting value and the interval you are comparing it against is a fasting one.

What is the plan if the drift continues for another month?

Correction: that trial measured regain after withdrawal, not failure of the drug during treatment. Very different claim.

What is the plan if the drift continues for another month?

Correction: that marker is reported in different units by different labs, which explains the tenfold difference you are seeing.

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

SURMOUNT-1 landed around 21% at 72 weeks on the top arm